Tatsufumi Ishibashi

Sumitomo Mitsui Banking Corp. engages in the provision of financial services centered on banking. It operates through the following business segments: Wholesale, Retail, International, Market Sales, and Headquarters Management. The Wholesale segment covers business for customers of large and medium-sized companies in Japan. The Retail segment handles business for domestic individuals and SME customers. The International segment comprises of business for overseas Japanese and non-Japanese companies. The Market Sales segment corresponds to financial market business. The Headquarters Management segment includes all other businesses not covered by other segments. The company was founded in April 2001 and is headquartered in Tokyo, Japan.

Ginsen Co., Ltd. engages in the general insurance agency, life insurance agency, building, parking lots and real estate consulting businesses. The company was founded in May 1954 and is headquartered in Osaka, Japan.

DX Antenna Co. Ltd. manufactures antenna and other networking equipment. The firm’s products include optical transmitters/receivers, BS antennas, CS antennas, CS/BS multi-beam antennas, wireless LAN antennas, CS/BS receivers, headend devices, two way CATV amplifiers, channel proper amplifiers, converters, level controllers, UHF antennas, VHF antennas, FM antennas, amateur radio antennas, and mixer/band separators. The company was founded on August 1, 1953 and is headquartered in Kobe-shi, Japan.

RBG Partners KK engages in the operation and management of investment business partnership assets. It also deals with the acquisition and holding of securities and offers consulting services for company diagnosis and investment planning. The company was founded on October 2, 2018 and is headquartered in Yokohama, Japan.

Part of Kaken Pharmaceutical Co., Ltd., ARTham Therapeutics, Inc. is a pharmaceutical company based in Yokohama, Japan. The Japanese company's mission is to deliver "medicines that matter" to improve patient health and contribute to enhanced quality of life through the development of innovative disease-modifying medicines. The company was founded by Sham Nikam, Naoto Uemura, and has been led by CEO Hiroshi Nagabukuro since 2018. ARTham Therapeutics was acquired by Kaken Pharmaceutical Co., Ltd. on December 13, 2021 for $111.95 million.